

Pregnancy-induced hypertension-related chorioretinitis resembling uveal effusion syndrome

A case report

Tomohito Sato, MD, PhD, Masaru Takeuchi, MD, PhD*

Abstract

Rationale: Pregnancy-induced hypertension (PIH) is a major cause of maternal and fetal mortality. Hypertensive choroidopathy is a preliminary sign of vasogenic edema in the choroid, and is associated with PIH. Here, we report a post-natal case of PIH-related chorioretinitis with bilateral severe serous retinal detachment (SRD) resembling uveal effusion syndrome.

Patient concerns: A 35-year-old woman was diagnosed with severe PIH at 37 weeks of pregnancy. She underwent an emergency cesarean delivery. Four days after delivery, she perceived a sudden decrease of vision. At presentation, fundus examination demonstrated bullous SRD and multiple white mottles in the posterior poles of both eyes. Optical coherence tomography (OCT) showed macula edema and retinal pigment epithelium (RPE) folds. Indocyanine green angiography (ICGA) demonstrated delayed filling of choroidal circulation in the early phase and multiple hyperfluorescent spots in the mid phase.

Diagnoses: PIH.

Interventions: Antihypertension treatment alone resulted in gradual resolution of the SRD.

Outcomes: At 463 days after delivery, fundus photographs of both eyes showed leopard spots corresponding to hyperautofluorescent spots with dark rim observed on fundus autofluorescence images.

Lessons: Ophthalmologists should be aware of PIH-related chorioretinitis with similar clinical manifestations as uveal effusion syndrome, and should treat with antihypertensive agents in cooperation with obstetricians.

Abbreviations: $\beta 2m = \beta 2$ -microglobulin, 1h = 1 hour, ACE = angiotensin converting enzyme, AH = aqueous humor, ALT = alanine aminotransferase, ANA = antinuclear antibody, APTT = activated partial thromboplastin time, AST = aspartate transaminase, BCVA = best-corrected visual acuity, bFGF = basic fibroblast growth factor, BP = blood pressure, BUN = blood urea nitrogen, CFF = critical fusion frequency, CH50 = hemolytic complement activity, CRP = C-reactive protein, CSF = cerebrospinal fluid, DBP = diastolic blood pressure, eGFR = estimate glomerular filtration rate, ERR = erythrocyte sedimentation rate, FA = fluorescein angiography, FAF = fundus autofluorescence, FBS = fasting blood sugar, G-CSF = granulocyte colony-stimulating factor, GM-CSF = granulocyte macrophage colony-stimulating factor, GP = Goldmann perimetry, Hb = hemoglobin, HbA1c = hemoglobin A1c, HLA = human leukocyte antigen, Ht = hematocrit, ICGA = indocyanine green angiography, IFN- γ = interferon-gamma, Ig = immunoglobulin, IL = interleukin, IL-1ra = IL-1 receptor antagonist, IP-10 = interferon gamma-induced protein 10, LDH = lactate dehydrogenase, MBP = myelin basic protein, MCP-1 = monocyte chemotactic protein-1, MIP = macrophage inflammatory protein, normal T-cell expressed and secreted, OCT = optical coherence tomography, PDGF = platelet derived growth factor, PIH = pregnancy-induced hypertension, PT = prothrombin time, PT-INR = prothrombin time-international normalized ratio, RANTES = regulated on activation, RBC = red blood cell, RF = rheumatoid factor, RPE = retinal pigment epithelium, SBP = systolic blood pressure, SD-OCT = spectral-domain optical coherence tomography, SRD = serous retinal detachment, T-Bil = total bilirubin, TNF α = tumor necrosis factor alpha, VEGF = vascular endothelial growth factor, VKH = Vogt–Koyanagi–Harada, WBC = white blood cell.

Keywords: pregnancy-induced hypertension, serous retinal detachment, uveal effusion syndrome

Editor: N/A.

Competing interests: None.

Dual Publication: None.

Patient consent: Obtained.

The authors have no funding and no conflicts of interest to disclose.

Department of Ophthalmology, National Defense Medical College, Saitama, Japan.

* Correspondence: Masaru Takeuchi, Department of Ophthalmology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan (e-mail: masatake@ndmc.ac.jp).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2018) 97:30(e11572)

Received: 5 March 2018 / Accepted: 28 June 2018

http://dx.doi.org/10.1097/MD.000000000011572

1. Introduction

Pregnancy-induced hypertension (PIH) is a complication resulting in maternal, fetal and newborn morbidity and mortality, in which there are central nervous system dysfunction, hepatocellular injury, thrombocytopenia, acute disseminated intravascular coagulation, oliguria, pulmonary edema, cerebrovascular events and placental abruption.^[1] In ophthalmology, PIH could induce acute retinal pigment epitheliopathy when malignant hypertension causes sudden choroidal ischemia.^[2] Hypertensive choroidopathy is a preliminary sign of vasogenic edema in the choroid, and is associated with PIH.^[3,4]

Uveal effusion syndrome is a rare condition characterized by idiopathic spontaneous serous detachment of the retina and peripheral choroid, suggesting a primary scleral abnormality.^[5] Uveal effusion syndrome may be caused by a variety of disease states such as postoperative hypotony, scleral buckling procedures and scleritis.^[6] On the other hand, the syndrome may occur spontaneously with no apparent cause in one or both eyes of healthy individuals, particularly in middle-aged males.^[6]



Figure 1. Visual field and fundus findings at 5 days after delivery. GP shows central scotomas over 20° in central visual field of the right eye (A) and left eye (B). Fundus images show bullous SRDs and multiple white mottles in the right eye (C) and left eye (D). OCT demonstrates macula edema and folds of the RPE layer in the right eye (E) and left eye (F). GP = Goldmann perimetry, OCT = optical coherence tomography, RPE = retinal pigment epithelium, SRD = serous retinal detachment.



Figure 2. Angiographic findings of the right eye at 5 days after delivery. FA images show no delayed filling of retinal circulation in the early phase (A), multiple dye leakages in the mid phase (B) and poolings in the late phase (C). ICGA images demonstrate delayed filling of choroidal circulation in the early phase (D), multiple hyperfluorescent spots in the mid phase (E) and dye poolings in the late phase (F). FA=fluorescein angiography, ICGA=indocyanine green angiography.

In this report, we present a case of PIH-related chorioretinitis with bilateral severe serous retinal detachment (SRD) resembling uveal effusion syndrome occurring after delivery, and discuss clinical features of the chorioretinitis.

2. Case report

This study protocol was not approved by the Ethics Committee of National Defense Medical College as it was not deemed necessary, this being a retrospective case report. The Declaration of Helsinki was followed in this case report. Patient consent has been obtained for the publication of the contents in this report. A 35-year-old woman was diagnosed with severe PIH at 37 weeks of pregnancy, with blood pressure (BP) of 180/110 mm Hg.^[7] She underwent an emergency cesarean delivery. At the age of 29, she had undergone laser-assisted in-situ keratomileusis for correcting

7.0 D myopia in both eyes. Four days after delivery, she perceived a sudden decrease of vision. She had no nonspecific viral infection and no systemic symptoms such as headache, vertigo, and tinnitus before the sudden decrease of vision. At 5 days after delivery, she was referred to the National Defense Medical College Hospital, Japan. At presentation, her BP had decreased to 150/90 mm Hg, and her best-corrected visual acuity (BCVA) was 20/100 in both eyes. Critical fusion frequency (CFF) was 18 Hz in both eyes. Axial length was 24.83 mm in the right eye and 24.79 mm in the left eye. Goldmann perimetry (GP) demonstrated central scotomas over 20° in central visual fields of both eves (Fig. 1A and B). Ophthalmoscopy showed no inflammatory cell in the anterior chamber and anterior vitreous cavity, but revealed apparent SRD and multiple white mottles in the posterior poles of both eyes (Fig. 1C and D). Spectral-domain optical coherence tomography (SD-OCT) (Heidelberg Engineering, Heidelberg,

Hematologic data in the acute phase

Table 1

Hematologic c	data in the acu	ute phase.					
Item	Result	Unit	Reference range	Item	Result	Unit	Reference range
Blood count				Immunity			
RBC count	3.90	$ imes$ 10 ⁶ / μ L	3.80-4.40	CRP	1.4	mg/dL	≦0.3
Hb	10.6	g/dL	12.0-15.0	lgG	545	mg/dL	870-1700
Ht	32.7	%	34.0-44.0	IgA	165	mg/dL	110-410
WBC count	9.90	$\times 10^3 / \mu L$	4.0-8.0	IgM	80	mg/dL	35-220
Neutrophil	79.8	%	44.0-74.0	β2m	1.6	mg/L	0.7-2.0
Lymphocyte	14.9	%	20.0-50.0	CH50	93	U/mL	31–58
Other	5.3	%	0-21.0	C3	118	mg/dL	65-135
Platelet count	17.8	$ imes$ 10 ⁴ / μ L	15.0-40.0	C4	25	mg/dL	13–35
Biochemistry	55	U/L	8–30	RF	≦ 20	IU/mL	≦ 20
T-Bil	0.9	mg/dL	0.2-1.2	ANA	40	times	< 40 times
AST	55	U/L	8–30	ESR (1 h)	19	mm	3–11
ALT	66	U/L	5-35	Coagulation			
LDH	458	U/L	100-225	PT			
Total protein	5.0	g/dL	6.5-8.2	Activity %	126.0	%	80.0 -110.0
FBS	100	mg/dL	65-110	PT-INR	0.92		0.9-1.1
HbA1c	5.2	%	4.6-6.2	APTT			
BUN	16	mg/dL	8-20	Time	27.1	seconds	24.0-34.0
Creatinine	0.45	mg/dL	0.44-0.78	Fibrinogen	273	mg/dL	180-400
ACE	11.4	IU/L	7.7-29.4				
eGFR	123.8	mL/min/1.73 m ²					

ACE = angiotensin converting enzyme, ALT = alanine aminotransferase, ANA = antinuclear antibody, APTT = activated partial thromboplastin time, AST = aspartate transaminase, BUN = blood urea nitrogen, CH50 = hemolytic complement activity, CRP = C-reactive protein, eGFR = estimate glomerular filtration rate, ERR = erythrocyte sedimentation rate, FBS = fasting blood sugar, Hb = hemoglobin, HbA1c = hemoglobin A1c, Ht = hematocrit, Ig = immunoglobulin, LDH = lactate dehydrogenase, PT = Prothrombin time, PT-INR = prothrombin time-international normalized ratio, RBC = red blood cell, RF = rheumatoid factor, T-Bil = total bilirubin, WBC = white blood cell, $\beta 2m = \beta 2$ -microglobulin, 1 h = 1 hour.

Germany, and Carl Zeiss Meditec AG, Jena, Germany) demonstrated macula edema and retinal pigment epithelial (RPE) folds (Fig. 1E and F). Fluorescein angiography (FA) showed multiple dye leakages in the mid phase (2 minutes after injection) (Fig. 2B) and multiple poolings in the late phase (11 minutes) (Fig. 2C). Indocyanine green angiography (ICGA) demonstrated delayed filling of the choroidal circulation in the early phase (58 seconds) (Fig. 2D), multiple hyperfluorescent spots in the mid phase (4 minutes) (Fig. 2E) and multiple poolings in the late phase (10 minutes) (Fig. 2F). The results of hematologic, urine, and cerebrospinal fluid (CSF) test were shown in Table 1, Table 2 and Table 3, respectively, and most of those were within normal limits. Aqueous humor levels of interleukin (IL)-6, interferon-inducible protein 10 and vascular

endothelial growth factor were 14.3, 890.3 and 24.4 pg/mL, respectively (Table 4). Serum immunological tests were negative for human leukocyte antigen (HLA)-DR4, -DR53, -DQ4, and -DRβ1*04. At 13 days after delivery, GP revealed alleviation of large central scotomas but persistence under 5° in central visual field, and expansion of Marriott's blind spots in both eyes (Fig. 3A and B). Funduscopy showed that the bullous SRDs were resolved, and multiple white mottles were attenuated but remained in both eyes (Fig. 3C and D). SD-OCT revealed choroidal thickening, alleviation of the RPE folds and multiple sub- and epi-RPE deposits with high brightness (Fig. 3E and F). FA showed multiple hypofluorescent spots and a few hyper-fluorescent spots in the mid-phase (2 minutes) (Fig. 4B) and dye poolings at the hyperfluorescent spots during the late phase

Table 2						
Urine data in the acute phase.						
Item	Result	Reference range				
Specific weight	1.015	1.010-1.030				
рН	7.0	5.0-8.0				
Protein	(3+)	(—)				
Glucose	(—)	()				
Occult blood	(1+)	(—)				
Ketone body	(—)	()				
Bilirubin	(—)	()				
Urobilinogen	(—)	()				
WBC	(1+)	()				
Nitrite	(—)	()				
Color tone	Light yellow	Light yellow-yellow				
Opacity	(—)	(—)				

WBC=white blood cell.

- - - -

Table 3						
Cerebrospinal fluid data in the acute phase.						
Item	Result	Unit	Reference range			
Xanthochromia	(—)		(—)			
Bloody	(—)		(—)			
Suspended matter	(\pm)		(—)			
Fibrin clot	(—)		(—)			
Cell population	≦1	/µL	≦6			
Specific weight	1.005		1.005-1.007			
PH	8.2		7.2-7.6			
Protein	18	mg/dL	10-40			
Glucose	56	mg/dL	50-75			
lgG	1.3	mg/dL	2.0-4.0			
MBP	≦40.0	pg/mL	≦102			
Oligoclonal band	Negative		Negative			

CSF = cerebrospinal fluid, Ig = immunoglobulin, MBP = myelin basic protein.

Table 4

serum, cerebrospinal huid and aqueous numor levels of cytokines in the acute phase.							
Cytokines	Serum	CSF	AH	Cytokines	Serum	CSF	AH
PDGF-BB	39.5	0	0	IL-17A	0	0	0
IL-1β	0	0	0	Eotaxin	0	0	0
IL-1ra	0	0	0	bFGF	0	26	0
IL-2	0	0	0	G-CSF	0	0	0
IL-4	4.67	0	0	GM-CSF	0	0	0
IL-5	0	0	0	IFN-γ	0	18.7	0
IL-6	0	5.65	14.3	IP-10	0	1018	890.3
IL-7	4.87	31.1	3.77	MCP-1	0	66.9	300
IL-8	6.21	44.3	12.4	MIP-1α	0	0.52	0
IL-9	10.5	0	0	MIP-1β	0	10.5	20.4
IL-10	0	0	0	RANTES	104.6	0	0
IL-12	0	0	0	τΝFα	0	0	0
IL-13	0	13.9	0	VEGF	0	0	24.4
IL-15	0	0	0				

and human lands of antakings in the south shoot

Cytokine level is expressed by pg/mL. Levels of cytokines below detection limits were assigned a numerical value of 0 pg/mL. AH = aqueous humor, bFGF = basic fibroblast growth factor, CSF = cerebrospinal fluid, G-CSF = granulocyte colony-stimulating factor, GM-CSF = granulocyte macrophage colony-stimulating factor, IFN- γ = interferon-gamma, IL = interleukin, IL-1ra = IL-1 receptor antagonist, IP-10 = interferon gamma-induced protein 10, MCP-1 = monocyte chemotactic protein-1, MIP = macrophage inflammatory protein, PDGF = platelet derived growth factor, RANTES = regulated on activation, normal T-cell expressed and secreted, TNF α = tumor necrosis factor alpha, VEGF = vascular endothelial growth factor.

(10 minutes) (Fig. 4C). On ICGA images, delayed filling of the choroidal circulation in the early phase (13 seconds) was resolved (Fig. 4D), but multiple hypofluorescent spots remained, which corresponded to the hypofluorescent spots observed on FA in the late phase (9 minutes) (Fig. 4F). The SRDs gradually disappeared with only antihypertension treatment. Based on laboratory data and clinical course, PIH-related chorioretinitis but not Vogt-Koyanagi-Harada (VKH) disease was diagnosed as the cause of bilateral SRD. At 42 days after delivery, the SRDs in both eyes completely vanished. At 97 days after delivery, central scotomas and expansion of Marriott's blind spots were not observed by GP in both eyes (Fig. 4G and H). At 189 days after delivery, her BCVA recovered to be 20/20 in both eyes. CFF was 42 Hz in both eyes. At 463 days after delivery, fundus photographs demonstrated leopard spots in both eyes (Fig. 5A and B), which corresponded to hyperautofluorescent spots with dark rim on fundus autofluorescence (FAF) images (Fig. 5C and D). SD-OCT revealed focal deposits in the RPE layer corresponding to the hyperautofluorescent spots on FAF images (Fig. 5 E and F). The leopard spot pattern with hyperautofluorescence on FAF images was attenuated but remained even after 3 years (Fig. 5G and H).

3. Discussion

Hypertensive disorders of pregnancy including pregnancyinduced hypertension (PIH) develop approximately 10% of all pregnant women in the world.^[1] PIH has been established as follows: systolic blood pressure (SBP) and diastolic blood pressure (DBP) are higher than 140/90 mm Hg.^[1,7] In ophthalmology, cortical blindness and central serous chorioretinopathy are known as PIH-related ocular diseases.^[8,9] However, secondary SRD after delivery is rare, and only a few papers described case reports of PIH patients with SRD, which developing after delivery.^[10–12]

In monkey models, malignant hypertension induced choroidal fibrinoid necrosis, choriocapillaris nonperfusion, ischemic necrosis of RPE, compromise of the outer blood–retinal barrier and localized RPE detachment and/or SRD.^[13] Hypertensive choroidopathy is a manifestation of vasogenic edema of the choroid, and is associated with malignant hypertension, renal disease, pheochromocytoma and PIH.^[3,4] PIH-related retinochoroidal disorders could be divided into 3 types as follows: hypertensive retinopathy, characterized by retinal vascular occlusion with cotton wool patches, hypertensive choroidopathy (choroidal type), characterized by choroidal vascular occlusion with SRD, and mixed type, consisting of chorioretinal vascular occlusion.^[10,14] Our patient manifested bilateral bullous SRD but no cotton wool patches. SD-OCT revealed choroidal thickening and multiple RPE folds. Therefore, we consider that our patient developed the choroidal type of PIH rather than the retinal or combined type.

Uveal effusion syndrome has been recognized to be an abnormal condition, pooling fluid in the suprachoroidal space.^[15,16] Uveal effusion syndrome is classified into 3 subtypes based on the anatomical features as follows: type 1, an extreme small eye ball with highly hypermetropia, type 2, which a normal range size of eye ball with small ametropia, and type 3, a normal size eyeball. [17,18] Leopard spots by proliferation and migration of RPE cells are observe in uveal effusion syndrome,^[5] that are presented by multiple hypofluorescent spots on FA and ICGA.^[6,17,18] Furthermore, Okuda et al^[19] reported FAF images of leopard spots showing hyperautofluorescence in a patient with uveal effusion syndrome. In our patient, the eyeball size was not small but normal or rather large, and the findings of fundus, angiographic and FAF images were consistent with those of uveal effusion syndrome. Therefore, we speculate that the bilateral bullous SRD in this patient may have been induced by type 3 uveal effusion syndrome associated with choroidal type of PIH.

When blood-retinal barrier is impaired by inflammation, infection, neoplastic diseases, and retinal vascular occlusive diseases, SRD subsequently occurs.^[20] Several previous reports demonstrated post-natal SRD associated with PIH but the etiology remained unknown.^[10-12] The clinical features of SRD associated with PIH are similar to those observed in VKH



Figure 3. Visual field and fundus findings at 13 days after delivery. GP reveals central scotomas under 5° in central visual field, and expansion of Marriott's blind spots in the right eye (A) and left eye (B). Fundus photographs show resolution of bullous SRD, but persistence of multiple white mottles in the right eye (C) and left eye (D). OCT reveals choroidal thickening, alleviation of RPE folds, and multiple sub- and epi-RPE deposits with high brightness in the right eye (E) and left eye (F). GP=Goldmann perimetry, OCT=optical coherence tomography, RPE=retinal pigment epithelium, SRD=serous retinal detachment.

disease.^[10] On the other hand, medical treatments of the 2 diseases are absolutely different. While the major treatment of PIH is BP management guided by obstetricians, VKH disease is generally treated with systemic and topical corticosteroids by ophthalmologists. At the acute phase of VKH disease, the clinical features are characterized by sudden blurred vision, bilateral posterior uveitis, diffuse granulomatous choroiditis with exudative retinal detachment, vitritis, and optic disc swelling.^[21] In VKH disease patients, inflammation and infiltration of inflammatory cells trigger changes of vascular permeability resulting in choroidal thickening, and RPE folds are observed over 70% of the eyes in these patients.^[22,23] ICGA images of VKH patients show characteristic multiple dark dots that are inflammatory granulomas with filling defects.^[24,25] Our patient had no

prodromal symptoms, and ICGA showed no characteristic multiple dark dots. Furthermore, specific VKH disease-associated HLAs including HLA-B54, -DQ4, -DR4, -DR53 and -DRβ1*04 were negative in this patient.^[25,26] Leukocytes in the CSF were almost absent, and was not consistent with VKH disease in the acute phase.^[27] The IL-6 level in the aqueous humor of our patient was considerably low compared with that of VKH disease patients.^[28] During the clinical course, she recovered promptly under only antihypertensive treatment. Therefore, although the clinical features of PIH-related chorioretinitis are apparently similar to those of VKH disease, the underlying pathophysiology of SRD is different from that of VKH disease.

In conclusion, PIH-related chorioretinitis is a rare disease and the major treatment of PIH is BP management guided by



Figure 4. Angiographic findings of the right eye at 13 days after delivery, and visual field findings at 97 days after delivery. FA images show normal filling of retinal circulation in the early phase (A), multiple hypofluorescent spots and a few hyperfluorescent spots in the mid phase (B) and dye poolings at the hyperfluorescent spots during the late phase (C). ICGA images demonstrate normal filling of choroidal circulation in the early phase (D), and multiple hypofluorescent spots corresponding to the hypofluorescent spots observed on FA in the mid phase (E) and late phase (F). Central scotomas and expansion of Marriott's blind spots were not detected by GP in the right eye (G) and left eye (H). FA=fluorescein angiography, GP=Goldmann perimetry, ICGA=indocyanine green angiography.



Figure 5. Fundus findings at 463 days and 3 years after delivery. At 463 days after delivery, fundus photographs demonstrate leopard spots in the right eye (A) and left eye (B). FAF images show hyperautofluorescent spots with dark rim corresponding to the leopard spots in the right eye (C) and left eye (D). OCT reveals focal deposits in the RPE layer corresponding to the hyperautofluorescent spots on FAF image in the left eye (E and D; white arrow). At 3 years after delivery, the leopard spot pattern with hyperautofluorescence spots on FAF images was attenuated but remained in the right eye (G) and left eye (H). FAF = fundus autofluorescence, OCT = optical coherence tomography, RPE = retinal pigment epithelium.

obstetricians. To select appropriate treatment option, ophthalmologists should be aware of PIH-related chorioretinitis with similar clinical manifestations of uveal effusion syndrome, and treat it with antihypertensive agents in cooperation with obstetricians.

Author contributions

Conceptualization: Masaru Takeuchi. **Data curation:** Tomohito Sato. **Investigation:** Tomohito Sato. Resources: Masaru Takeuchi.

Writing - original draft: Tomohito Sato.

Writing - review & editing: Masaru Takeuchi.

References

- Kintiraki E, Papakatsika S, Kotronis G, et al. Pregnancy-induced hypertension. Hormones 2015;14:211–23.
- [2] Hayreh SS, Servais GE, Virdi PS, et al. Fundus lesions in malignant hypertension. Ophthalmology 1986;93:45-59.
- [3] Tso MO, Jampol LM. Pathophysiology of hypertensive retinopathy. Ophthalmology 1982;89:1132-45.
- [4] Kinyoun JL, Kalina RE. Visual loss from choroidal ischemia. Am J Ophthalmol 1986;101:650–6.
- [5] Forrester JV, Lee WR, Kerr PR, et al. The uveal effusion syndrome and trans-scleral flow. Eye (Lond) 1990;4:354–65.
- [6] Gass JD. Uveal effusion syndrome. A new hypothesis concerning pathogenesis and technique of surgical treatment. Retina 1983;3:159–63.
- [7] Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010;341:c2207.
- [8] Dinn RB, Harris A, Marcus PS. Ocular changes in pregnancy. Obstet Gynecol Surv 2003;58:137–44.
- [9] Schultz KL, Birnbaum AD, Goldstein DA. Ocular disease in pregnancy. Curr Opin Ophthalmol 2005;16:308–14.
- [10] Aoyagi R, Hayashi T, Tsuneoka H. Choroidal thickening and macular serous retinal detachment in pregnancy-induced hypertension. Int Med Case Rep J 2015;8:291–4.
- [11] Song YS, Kinouchi R, Ishiko S, et al. Hypertensive choroidopathy with eclampsia viewed on spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2013;251:2647–50.
- [12] Dewilde E, Huygens M, Cools G, et al. Hypertensive choroidopathy in pre-eclampsia: two consecutive cases. Ophthalmic Surg Lasers Imaging Retina 2014;45:343–6.
- [13] Kishi S, Tso MO, Hayreh SS. Fundus lesions in malignant hypertension: I. A pathologic study of experimental hypertensive choroidopathy. Arch Ophthalmol 1985;103:1189–97.
- [14] Saito Y. Retinochoroidal changes in toxemia of pregnancy with the relation to hypertensive retinopathy and choroidopathy. Nippon Ganka Gakkai Zasshi 1990;94:748–55.

- [15] Sakai H, Yonahara M, Sakai M. Recurrent uveal effusion after laser iridotomy. Case Rep Ophthalmol 2017;8:26–30.
- [16] Bellows AR, Chylack LTJr, Hutchinson BT. Choroidal detachment. Clinical manifestation, therapy and mechanism of formation. Ophthalmology 1981;88:1107–15.
- [17] Uyama M, Takahashi K, Kozaki J, et al. Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology. Ophthalmology 2000;107:441–9.
- [18] Gass JDM, Jallow S. Idiopathic serous detachment of the choroid, ciliary body, and retina (uveal effusion syndrome). Ophthalmology 1982; 89:1018–32.
- [19] Okuda T, Higashide T, Wakabayashi Y, et al. Fundus autofluorescence and spectral-domain optical coherence tomography findings of leopard spots in nanophthalmic uveal effusion syndrome. Graefes Arch Clin Exp Ophthalmol 2010;248:1199–202.
- [20] Amer R, Nalci H, Yalcindag N. Exudative retinal detachment. Surv Ophthalmol 2017;62:723–69.
- [21] Attia S, Khochtali S, Kahloun R, et al. Vogt-Koyanagi-Harada disease. Expert Rev Ophthalmol 2012;7:565–85.
- [22] Ishihara K, Hangai M, Kita M, et al. Acute Vogt-Koyanagi-Harada disease in enhanced spectral-domain optical coherence tomography. Ophthalmology 2009;116:1799–807.
- [23] Kato Y, Yamamoto Y, Tabuchi H, et al. Retinal pigment epithelium folds as a diagnostic finding of Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 2013;57:90–4.
- [24] Herbort CP, Mantovani A, Bouchenaki N. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up. Int Ophthalmol 2007;27: 173-82.
- [25] Weisz JM, Holland GN, Roer LN, et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology 1995;102: 1012–5.
- [26] Shi T, Lv W, Zhang L, et al. Association of HLA-DR4/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: a systematic review and metaanalysis. Sci Rep 2014;4:6887.
- [27] Norose K, Yano A, Aosai F, et al. Immunologic analysis of cerebrospinal fluid lymphocytes in Vogt–Koyanagi–Harada disease. Invest Ophthalmol Vis Sci 1990;31:1210–6.
- [28] Norose K, Yano A, Wang XC, et al. Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994;35:33–9.